Curis is seeking regulatory approval for its drug candidate emavusertib, having received Orphan Drug Designations from both the FDA and EMA.
1 report, 1 independent
Updated Aug 5
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Curis is seeking regulatory approval for its drug candidate emavusertib, having received Orphan Drug Designations from both the FDA and EMA.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
Curis (United States)
company in Lexington, United States
Nothing else this week.
Related events
- Kazia Therapeutics Limited is seeking various regulatory designations from the FDA to support its drug development pipeline.
- A Patient Assistance Program has been established to cover prescription medications that have received FDA approval.
- A product, NitroMist®, requires FDA approval for sale, and distributor access is being established for federal supply channels.
- EyePoint Pharmaceuticals developed its LUCIA trial program in alignment with the FDA, with enrollment noted in Lugano.
- Both the FDA and the European Medicines Agency govern drug approval processes.
Coverage
Newest first; wire copies grouped- PR NewswireCuris Provides Second Quarter 2025 Business Update Management to host conference call and webcast today at 8:30 a.m. ET LEXINGTON, Mass., Aug. 5, 2025 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a bi